Compounds > alendronate
Page last updated: 2024-10-22

alendronate and Cardiovascular Diseases

alendronate has been researched along with Cardiovascular Diseases in 14 studies

alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.

Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.

Research Excerpts

ExcerptRelevanceReference
"To explore the incidence of atrial fibrillation (AF) and other cardiovascular endpoints in clinical trials of alendronate."8.88Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. ( Barrett-Connor, E; Bone, HG; de Papp, A; Hustad, CM; Liberman, UA; Papapoulos, S; Santora, AC; Swern, AS; Wang, H, 2012)
"The long-term follow-up of our JMC patient has provided insight on therapeutic strategies to control hypercalciuria, on the potential effects of alendronate on FGF23 levels, and on the lack of detectable cardiovascular disease at young adulthood after prolonged exposure to hypercalcemia."7.78Potential effects of alendronate on fibroblast growth factor 23 levels and effective control of hypercalciuria in an adult with Jansen's metaphyseal chondrodysplasia. ( Correa, PH; Ferraz-de-Souza, B; Martin, RM; Mendonca, BB; Onuchic, L, 2012)
"We aimed to investigate the risk of AF, stroke, or acute myocardial infarction (AMI) associated with the use of the bisphosphonates alendronate and raloxifene in patients with osteoporosis."7.77Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate. ( Hsieh, CF; Huang, WF; Lu, PY; Tsai, YW, 2011)
"To explore the incidence of atrial fibrillation (AF) and other cardiovascular endpoints in clinical trials of alendronate."4.88Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. ( Barrett-Connor, E; Bone, HG; de Papp, A; Hustad, CM; Liberman, UA; Papapoulos, S; Santora, AC; Swern, AS; Wang, H, 2012)
"The long-term follow-up of our JMC patient has provided insight on therapeutic strategies to control hypercalciuria, on the potential effects of alendronate on FGF23 levels, and on the lack of detectable cardiovascular disease at young adulthood after prolonged exposure to hypercalcemia."3.78Potential effects of alendronate on fibroblast growth factor 23 levels and effective control of hypercalciuria in an adult with Jansen's metaphyseal chondrodysplasia. ( Correa, PH; Ferraz-de-Souza, B; Martin, RM; Mendonca, BB; Onuchic, L, 2012)
"We aimed to investigate the risk of AF, stroke, or acute myocardial infarction (AMI) associated with the use of the bisphosphonates alendronate and raloxifene in patients with osteoporosis."3.77Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate. ( Hsieh, CF; Huang, WF; Lu, PY; Tsai, YW, 2011)
" The medications were pravastatin, a cholesterol-lowering drug for the prevention of cardiovascular disease; alendronate, a bisphosphonate for the treatment and prevention of osteoporosis; and aspirin, which is used for the prevention of cardiovascular disease."3.70Coverage by the news media of the benefits and risks of medications. ( Bero, L; Henry, D; Lee, K; Mah, C; Moynihan, R; Ross-Degnan, D; Soumerai, SB; Watkins, J, 2000)
"Osteoporosis and cardiovascular diseases are major public health issues."2.61Cardiovascular Outcomes of Romosozumab and Protective Role of Alendronate. ( Asadipooya, K; Weinstock, A, 2019)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (7.14)18.2507
2000's1 (7.14)29.6817
2010's10 (71.43)24.3611
2020's2 (14.29)2.80

Authors

AuthorsStudies
Cummings, SR1
McCulloch, C1
Holdsworth, G1
Staley, JR1
Hall, P1
van Koeverden, I1
Vangjeli, C1
Okoye, R1
Boyce, RW1
Turk, JR1
Armstrong, M1
Wolfreys, A1
Pasterkamp, G1
Saag, KG1
Petersen, J1
Brandi, ML1
Karaplis, AC1
Lorentzon, M1
Thomas, T1
Maddox, J1
Fan, M1
Meisner, PD1
Grauer, A1
Sing, CW2
Wong, AY2
Kiel, DP2
Cheung, EY2
Lam, JK2
Cheung, TT2
Chan, EW2
Kung, AW2
Wong, IC2
Cheung, CL2
Tran, TS1
Nguyen, TV1
Giollo, A1
Rossini, M1
Gatti, D1
Adami, G1
Orsolini, G1
Fassio, A1
Caimmi, C1
Idolazzi, L1
Viapiana, O1
Asadipooya, K1
Weinstock, A1
Connolly, JG1
Gagne, JJ1
Barrett-Connor, E1
Swern, AS1
Hustad, CM1
Bone, HG1
Liberman, UA1
Papapoulos, S1
Wang, H1
de Papp, A1
Santora, AC1
Lu, PY1
Hsieh, CF1
Tsai, YW1
Huang, WF1
Onuchic, L1
Ferraz-de-Souza, B1
Mendonca, BB1
Correa, PH1
Martin, RM1
Goldstein, MR1
Moynihan, R1
Bero, L1
Ross-Degnan, D1
Henry, D1
Lee, K1
Watkins, J1
Mah, C1
Soumerai, SB1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis[NCT01631214]Phase 34,093 participants (Actual)Interventional2012-05-04Completed
Effects of Romosozumab on Bone Health in Women With Spinal Cord Injury and Osteoporosis[NCT04708886]Phase 212 participants (Anticipated)Interventional2021-03-01Active, not recruiting
Risedronate With High-dose Vitamin D Resolves Hyperparathyroidism and Hypovitaminosis D But Not Osteoporosis in Mexican Postmenopausal Patients[NCT05346419]33 participants (Actual)Interventional2021-07-01Completed
Vitamin D Improves Osteoporosis in Postmenopausal Women With Denosumab Failure[NCT05372224]55 participants (Actual)Interventional2020-06-22Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percent Change From Baseline in Bone Mineral Density at the Femoral Neck at Month 12

Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 12

Interventionpercent change (Least Squares Mean)
Alendronate/Alendronate1.7
Romosozumab/Alendronate4.9

Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12

Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 12

Interventionpercent change (Least Squares Mean)
Alendronate/Alendronate5.0
Romosozumab/Alendronate13.7

Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 24

Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 24

Interventionpercent change (Least Squares Mean)
Alendronate/Alendronate7.2
Romosozumab/Alendronate15.3

Percent Change From Baseline in Bone Mineral Density at the Total Hip at Month 12

Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 12

Interventionpercent change (Least Squares Mean)
Alendronate/Alendronate2.8
Romosozumab/Alendronate6.2

Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at at Month 24

Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 24

Interventionpercent change (Least Squares Mean)
Alendronate/Alendronate2.3
Romosozumab/Alendronate6.0

Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 36

Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 36

Interventionpercent change (Least Squares Mean)
Alendronate/Alendronate2.4
Romosozumab/Alendronate6.0

Percent Change From Baseline in Bone Mineral Density of the Lumbar Spine at Month 36

Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 36

Interventionpercent change (Least Squares Mean)
Alendronate/Alendronate7.8
Romosozumab/Alendronate15.2

Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24

Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 24

Interventionpercent change (Least Squares Mean)
Alendronate/Alendronate3.5
Romosozumab/Alendronate7.2

Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 36

Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 36

Interventionpercent change (Least Squares Mean)
Alendronate/Alendronate3.5
Romosozumab/Alendronate7.2

Percentage of Participants With a Clinical Fracture at the Primary Analysis

All fracture assessments were performed by blinded central imaging readers. Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).

Interventionpercentage of participants (Number)
Alendronate/Alendronate13.0
Romosozumab/Alendronate9.7

Percentage of Participants With a Clinical Fracture Through Month 12

Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Alendronate/Alendronate5.4
Romosozumab/Alendronate3.9

Percentage of Participants With a Clinical Fracture Through Month 24

Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: 24 months

Interventionpercentage of participants (Number)
Alendronate/Alendronate9.6
Romosozumab/Alendronate7.1

Percentage of Participants With a Clinical Vertebral Fracture Through Month 12

A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic. (NCT01631214)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Alendronate/Alendronate0.9
Romosozumab/Alendronate0.5

Percentage of Participants With a Clinical Vertebral Fracture Through Month 24

A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic. (NCT01631214)
Timeframe: 24 months

Interventionpercentage of participants (Number)
Alendronate/Alendronate2.1
Romosozumab/Alendronate0.9

Percentage of Participants With a Hip Fracture at the Primary Analysis

Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter. (NCT01631214)
Timeframe: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).

Interventionpercentage of participants (Number)
Alendronate/Alendronate3.2
Romosozumab/Alendronate2.0

Percentage of Participants With a Hip Fracture Through Month 12

Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter. (NCT01631214)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Alendronate/Alendronate1.1
Romosozumab/Alendronate0.7

Percentage of Participants With a Hip Fracture Through Month 24

Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter. (NCT01631214)
Timeframe: 24 months

Interventionpercentage of participants (Number)
Alendronate/Alendronate2.1
Romosozumab/Alendronate1.5

Percentage of Participants With a Major Nonvertebral Fracture at the Primary Analysis

Major nonvertebral fractures included a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip. (NCT01631214)
Timeframe: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).

Interventionpercentage of participants (Number)
Alendronate/Alendronate9.6
Romosozumab/Alendronate7.1

Percentage of Participants With a Major Osteoporotic Fracture Through Month 12

Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Alendronate/Alendronate4.2
Romosozumab/Alendronate3.0

Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 24

"A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:~Grade 0 (Normal) = no fracture;~Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);~Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;~Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.~Incident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method." (NCT01631214)
Timeframe: 24 months

Interventionpercentage of participants (Number)
Alendronate/Alendronate9.2
Romosozumab/Alendronate4.8

Percentage of Participants With a Nonvertebral Fracture at the Primary Analysis

A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).

Interventionpercentage of participants (Number)
Alendronate/Alendronate10.6
Romosozumab/Alendronate8.7

Percentage of Participants With a Nonvertebral Fracture Through Month 12

A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Alendronate/Alendronate4.6
Romosozumab/Alendronate3.4

Percentage of Participants With a Nonvertebral Fracture Through Month 24

A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: 24 months

Interventionpercentage of participants (Number)
Alendronate/Alendronate7.8
Romosozumab/Alendronate6.3

Percentage of Participants With Any Fracture at the Primary Analysis

All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures. (NCT01631214)
Timeframe: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).

Interventionpercentage of participants (Number)
Alendronate/Alendronate19.1
Romosozumab/Alendronate13.0

Percentage of Participants With Any Fracture Through Month 12

All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures. (NCT01631214)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Alendronate/Alendronate9.2
Romosozumab/Alendronate6.5

Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24

A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit. Incident vertebral fractures were confirmed by a second independent reader. (NCT01631214)
Timeframe: 24 months

Interventionpercentage of participants (Number)
Alendronate/Alendronate2.5
Romosozumab/Alendronate1.3

Percentage of Participants With New Vertebral Fractures Through Month 12

"New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:~Grade 0 (Normal) = no fracture;~Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);~Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;~Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.~Incident vertebral fractures were confirmed by a second independent reader." (NCT01631214)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Alendronate/Alendronate5.0
Romosozumab/Alendronate3.2

Percentage of Participants With New Vertebral Fractures Through Month 24

"All fracture assessments were performed by blinded central imaging readers.~New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:~Grade 0 (Normal) = no fracture;~Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);~Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;~Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.~Incident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method." (NCT01631214)
Timeframe: 24 months

Interventionpercentage of participants (Number)
Alendronate/Alendronate8.0
Romosozumab/Alendronate4.1

Reviews

2 reviews available for alendronate and Cardiovascular Diseases

ArticleYear
Cardiovascular Outcomes of Romosozumab and Protective Role of Alendronate.
    Arteriosclerosis, thrombosis, and vascular biology, 2019, Volume: 39, Issue:7

    Topics: Adaptor Proteins, Signal Transducing; Alendronate; Antibodies, Monoclonal; Cardiovascular Diseases;

2019
Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2012, Volume: 23, Issue:1

    Topics: Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Cardiovascular Diseases; Dose-Re

2012

Trials

1 trial available for alendronate and Cardiovascular Diseases

ArticleYear
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    The New England journal of medicine, 2017, 10-12, Volume: 377, Issue:15

    Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo

2017
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    The New England journal of medicine, 2017, 10-12, Volume: 377, Issue:15

    Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo

2017
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    The New England journal of medicine, 2017, 10-12, Volume: 377, Issue:15

    Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo

2017
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    The New England journal of medicine, 2017, 10-12, Volume: 377, Issue:15

    Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo

2017
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    The New England journal of medicine, 2017, 10-12, Volume: 377, Issue:15

    Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo

2017
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    The New England journal of medicine, 2017, 10-12, Volume: 377, Issue:15

    Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo

2017
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    The New England journal of medicine, 2017, 10-12, Volume: 377, Issue:15

    Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo

2017
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    The New England journal of medicine, 2017, 10-12, Volume: 377, Issue:15

    Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo

2017
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    The New England journal of medicine, 2017, 10-12, Volume: 377, Issue:15

    Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo

2017
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    The New England journal of medicine, 2017, 10-12, Volume: 377, Issue:15

    Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo

2017
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    The New England journal of medicine, 2017, 10-12, Volume: 377, Issue:15

    Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo

2017
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    The New England journal of medicine, 2017, 10-12, Volume: 377, Issue:15

    Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo

2017
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    The New England journal of medicine, 2017, 10-12, Volume: 377, Issue:15

    Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo

2017
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    The New England journal of medicine, 2017, 10-12, Volume: 377, Issue:15

    Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo

2017
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    The New England journal of medicine, 2017, 10-12, Volume: 377, Issue:15

    Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo

2017
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    The New England journal of medicine, 2017, 10-12, Volume: 377, Issue:15

    Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo

2017

Other Studies

11 other studies available for alendronate and Cardiovascular Diseases

ArticleYear
Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2020, Volume: 31, Issue:6

    Topics: Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Cardiovascular

2020
Sclerostin Downregulation Globally by Naturally Occurring Genetic Variants, or Locally in Atherosclerotic Plaques, Does Not Associate With Cardiovascular Events in Humans.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2021, Volume: 36, Issue:7

    Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Cardiovascular Diseases; Down-Regulation; Female

2021
Association of Alendronate and Risk of Cardiovascular Events in Patients With Hip Fracture.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2018, Volume: 33, Issue:8

    Topics: Aged; Aged, 80 and over; Alendronate; Cardiovascular Diseases; Cause of Death; Female; Hip Fractures

2018
Reply to: Association Between Alendronate and All-Cause Mortality and Cardiovascular Mortality Among Hip Fracture: An Alternative Explanation.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2018, Volume: 33, Issue:10

    Topics: Alendronate; Bone Density Conservation Agents; Cardiovascular Diseases; Hip Fractures; Humans

2018
Association Between Alendronate and All-Cause Mortality and Cardiovascular Mortality Among Hip Fracture: An Alternative Explanation.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2018, Volume: 33, Issue:10

    Topics: Alendronate; Cardiovascular Diseases; Hip Fractures; Humans

2018
Amino-Bisphosphonates and Cardiovascular Risk: A New Hypothesis Involving the Effects on Gamma-Delta T Cells.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2019, Volume: 34, Issue:3

    Topics: Alendronate; Cardiovascular Diseases; Diphosphonates; Humans; Receptors, Antigen, T-Cell, gamma-delt

2019
Comparison of Calipers for Matching on the Disease Risk Score.
    American journal of epidemiology, 2016, 05-15, Volume: 183, Issue:10

    Topics: Aged; Aged, 80 and over; Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conserva

2016
Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
    Clinical therapeutics, 2011, Volume: 33, Issue:9

    Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cardiovascular Diseases; Coh

2011
Potential effects of alendronate on fibroblast growth factor 23 levels and effective control of hypercalciuria in an adult with Jansen's metaphyseal chondrodysplasia.
    The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:4

    Topics: Adult; Alendronate; Bone Density Conservation Agents; Cardiovascular Diseases; Drug Therapy, Combina

2012
Long-term therapy for postmenopausal osteoporosis: stronger bones but weaker arteries.
    Circulation, 1999, Jul-27, Volume: 100, Issue:4

    Topics: Alendronate; Arteries; Cardiovascular Diseases; Female; Humans; Osteoporosis, Postmenopausal; Time F

1999
Coverage by the news media of the benefits and risks of medications.
    The New England journal of medicine, 2000, Jun-01, Volume: 342, Issue:22

    Topics: Alendronate; Anticholesteremic Agents; Aspirin; Biomedical Research; Cardiovascular Diseases; Confli

2000